Pharmtechnology, LLC
🇧🇾Belarus
- Country
- 🇧🇾Belarus
- Ownership
- Private
- Established
- 1991-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://ft.by/en/okomp-2
Clinical Trials
27
Active:0
Completed:20
Trial Phases
1 Phases
Phase 1:27
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
Phase 1
27 (100.0%)Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions
Phase 1
Recruiting
- Conditions
- Bioequivalence
- Interventions
- Drug: Prestarium® A tablet
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 50
- Registration Number
- NCT06213610
- Locations
- 🇷🇺
Ligand Research LLC, Moscow, Russian Federation
Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions
Phase 1
Recruiting
- Conditions
- Bioequivalence
- Interventions
- Drug: Perindopril/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg tablet / Triplixam® 10 mg/2.5 mg/10 mg tablet
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 50
- Registration Number
- NCT05940909
- Locations
- 🇷🇺
Ligand Research LLC, Moscow, Russian Federation
Bioequivalence Study of Two Formulations of Clopidogrel Film-coated Tablets 75 mg in Healthy Male Subjects Under Fasting Conditions
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05934799
- Locations
- 🇷🇺
State Autonomous Healthcare Facility of the Yaroslavl Region "Clinical Hospital No. 2", Yaroslavl, Yaroslavl Region, Russian Federation
Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting Conditions
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- Drug: Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 50
- Registration Number
- NCT05685277
- Locations
- 🇷🇺
Separate medical division "Comed" (Ligand Research LLC), Moscow, Russian Federation
Bioequivalence Study of Two Formulations of Atorvastatin Film-coated Tablets 40 mg in Healthy Volunteers Under Fasting Conditions
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- Drug: Liprimar® film-coated tablet 40 mg
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 50
- Registration Number
- NCT05642845
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of the Yaroslavl Region "Clinical Hospital No. 2", Yaroslavl, Russian Federation
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
No news found